DeğerQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSatış/genel/idari giderler1.52 B1.45 B1.5 B1.51 B1.53 B6 BAraştırma ve geliştirme106 M84 M91 M94 M98 M367 MFaaliyet karı483 M767 M692 M629 M535 M2.62 BFaaliyet Dışı Gelir, Toplam-42 M0-10 M-10 M-10 M-30 MFaiz gideri (aktifleştirilmiş faizler düşüldükten sonra)108 M106 M107 M107 M109 M429 MFaaliyet Dışı Gelir (Faiz Giderleri Hariç)-45 M-106 M-118 M-127 M-118 M-469 MOlağandışı gelirler/giderler3 M01 M10 M-1 M—Vergi öncesi kar346 M672 M588 M526 M427 M2.21 BKazançlardaki özsermayeler——————Vergiler53 M198 M168 M128 M97 M591 MKontrol gücü olmayan/azınlık payı——————Vergi sonrası diğer gelirler/giderler-33 M-18 M-17 M-21 M-13 M-69 MDurdurulan faaliyetler öncesi net kar293 M474 M420 M398 M330 M1.62 BDurdurulan faaliyetler——————Net kar293 M474 M420 M398 M330 M1.62 BSeyreltme ayarlaması——————İmtiyazlı temettüler——————Adi hisse senedi sahiplerine düşen seyreltilmiş net kar293 M474 M420 M398 M330 M1.62 BTemel hisse başına kazanç (Temel EPS)0.160.250.220.210.170.85Seyreltilmiş hisse başına kazanç (Seyreltilmiş EPS)0.160.250.220.210.160.84Dolaşımdaki ortalama adi hisse senedi sayısı1.92 B1.92 B1.92 B1.92 B1.92 B—Dolaşımdaki seyreltilmiş hisse senedi sayısı1.92 B1.92 B1.93 B1.92 B1.92 B—FAVÖK79 M703 M594 M529 M-6 M1.82 BFVÖK-83 M560 M452 M388 M-144 M1.26 BGelir maliyeti1.59 B1.61 B1.58 B1.54 B1.64 B6.37 BSatılan malların diğer maliyeti——————Amortisman ve itfa (nakit akışı)150 M143 M142 M141 M138 M564 M
Kenvue Inc. Common Stock
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.